⌕
Cara Therapeutics · TVRD · Nasdaq
Tenet 47 · Mixed
Compare
$0.95−9.03%At closeTenet 47 · Mixed
$0.95−0.09 (−9.03%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Cara Therapeutics (TVRD) Stock

Cara Therapeutics (TVRD) closed at $0.95 on Nov 19, 2026; its Tenet Score is 47 of 100 against 486 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$0.95
Nov 19, 2026
Market cap
$12.6M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
0.77 – 5.69
low → high
Tenet Score
47/100
Mixed · 486 Healthcare peers

Industry: Drugs · see every company filed here →

Cara Therapeutics, Inc. scores 47/100. Mixed. Strongest on value, quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 47 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=486
47/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
92
Quality
4
Health
45
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueAQualityFHealthDGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.8×
cap ÷ Sep 30, 2026 book value, Nov 19, 2026 close
P/S
—
no P/S on file
ROE
−145%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
2.86
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Cara Therapeutics, Inc.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The com…

Composite computed Nov 20, 2026 · peer basis: Healthcare (n=486) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 2 US ETFs · top wrappers by weightSee all ETFs holding TVRD →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Cara Therapeutics in?

Cara Therapeutics is in the Healthcare sector and the Drugs industry.

What is Cara Therapeutics' Tenet Score?

Cara Therapeutics' Tenet Score is 47 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.